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Diagnostic Assessment & Prognosis
Predicting time to dementia using a quantitative template of disease
progression
Murat Bilgela, Bruno M. Jedynakb,*, for the Alzheimer’s Disease Neuroimaging Initiative1
aLaboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
bDept. of Mathematics and Statistics, Portland State University, Portland, OR, USA
Abstract Introduction: Characterization of longitudinal trajectories of biomarkers implicated in sporadic
Alzheimer’s disease (AD) in decades before clinical diagnosis is important for disease prevention
and monitoring.
Methods: We used a multivariate Bayesian model to temporally align 1369 Alzheimer’s disease
Neuroimaging Initiative participants based on the similarity of their longitudinal biomarker measures
and estimated a quantitative template of the temporal evolution of cerebrospinal fluid Ab1242,
p-tau181p, and t-tau and hippocampal volume, brain glucose metabolism, and cognitive measure-
ments. We computed biomarker trajectories as a function of time to AD dementia and predicted
AD dementia onset age in a disjoint sample.
Results: Quantitative template showed early changes in verbal memory, cerebrospinal fluid Ab1–42
and p-tau181p, and hippocampal volume. Mean error in predicted AD dementia onset age was ,1:5
years.
Discussion: Our method provides a quantitative approach for characterizing the natural history of
AD starting at preclinical stages despite the lack of individual-level longitudinal data spanning the
entire disease timeline.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Alzheimer; Dementia; Onset; Prediction; Longitudinal; Biomarkers; Cognition; Quantitative template; Kaplan-
Meier
1. Background
Alzheimer’s disease (AD)–related brain changes,
including amyloid and phosphorylated tau deposition as
well as neurodegeneration, begin years before the emer-
gence of clinical dementia [1]. There is great interest in un-
derstanding the progression of biological and cognitive
markers (collectively referred to as biomarkers in this
article) that are implicated in AD in the earliest stages, given
that therapeutic intervention is hypothesized to be more
effective if administered early in the disease before down-
stream brain damage occurs. Such an understanding will
enable a better definition of preclinical AD and help identify
individuals who are likely to benefit from therapy.
In studies of dominantly inherited AD, parents’ ages at
disease onset serve as strong predictors of an individual’s
onset age, allowing the use of time from expected onset as
a surrogate of disease progression against which biomarker
trajectories can be characterized [2]; however, in sporadic
AD, such an estimate is not as good an indicator of expected
onset, making it difficult to characterize biomarker evolution
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in the earliest stages of neuropathology and neurodegenera-
tion that mark the preclinical stages of AD. Furthermore, dif-
ferences across individuals in the rate of disease progression
make it difficult to characterize a quantitative template (QT)
of biomarker changes as a function of disease state. There-
fore, it is necessary to use novel statistical approaches that
take into account such differences across individuals for
combining short-term follow-up data per individual to reveal
long-term biomarker trajectories.
Several studies have addressed this challenge of character-
izing biomarker trajectories in preclinical stages of AD as a
function of an underlying latent disease progression variable
that reflects the natural history of AD neuropathology, neuro-
degeneration, and cognitive changes via generative models.
These models emphasize the interpretability of model results
rather than optimization of predictive performance, where
discriminative methodsmight outperform but produce results
that are not as easily interpretable. Existing generative
models of AD progression can be divided into two major cat-
egories based on the granularity of their characterization of
the latent disease progression variable, either as a sequence
of discrete events [3–5] or as a continuous variable [6–14].
In addition to characterizing changes in biomarker
trajectories as a function of latent disease stages, these
statistical models provide individualized information that
can be used for personalized disease staging and monitoring.
Recent work in this area has focused on Bayesian refor-
mulations of statistical approaches to biomarker trajectory
modeling [11,14,15] to enable probabilistic estimates of
trajectories and better characterization of the individual-
level uncertainty in disease progression variables. These im-
provements can lead to better disease monitoring and pro-
gression prediction at the individual level, thereby
providing useful tools for clinical trial recruitment and
assessment. We further this line of research into continuous
latent disease progression models by reformulating our pro-
gression score models [6,7] as a Bayesian model and make
substantial changes to improve the interpretability of our
results. First, we impose weakly informative priors on
model parameters. This allows us to compute credible
intervals around estimated trajectories and individualized
disease stage indicators. Second, based on our earlier
observation that rate of progression is associated with
disease stage, we revise the transformation between age
and the latent disease progression variable, so that
biomarker trajectories can be depicted as a function of
time to diagnosis, which was not directly possible in our
previous model.
In addition to these substantial improvements to our pre-
viously described model, our work addresses several limita-
tions of previously described disease progression models.
(1) Existing disease progression score models formulated
in a Bayesian framework [11,14,15] specify the latent
disease progression variable using a single unknown
parameter, the time-shift, meaning that these models do
not take into account that disease progression may accelerate
over time, limiting their accuracy when working with
individual-level data over long periods of time. Our pro-
posed progression score (PS) takes this phenomenon into ac-
count through the use of an additional parameter in the
construction of PSs. (2) Current models either assume inde-
pendence across biomarkers [15], resulting in biased esti-
mates of latent disease scores [7], or impose linear [11] or
double exponential [14] parametric trajectories on bio-
markers, limiting the possible functions that can be esti-
mated, potentially resulting in mischaracterization of the
time evolution of biomarkers. We model biomarker time
courses using flexible monotonic nonlinear functions char-
acterized by basis functions. This allows for trajectory
models that are as versatile as those modeled via monotonic
gaussian processes as proposed by Lorenzi et al. [15], but
that do not require working with large covariance matrices
involved in the monotonic gaussian process setting. This
computational saving allows us to incorporate the correla-
tions among biomarkers to reduce the bias in the estimation
of PSs. (3) Although several classifiers have been developed
to predict a diagnostic label (i.e., cognitively normal [NL],
mild cognitive impairment [MCI], or AD;MCI nonconverter
vs. MCI converter) at the end of a fixed and short time frame
(typically ,3 years) given baseline biomarkers [16–22],
prior literature on continuous prediction of time to
dementia over longer periods is quite limited. We describe
a novel application of disease progression modeling results
for predicting time to dementia onset and propose the use
of Kaplan-Meier curves for assessing prediction accuracy.
Using our Bayesian Progression Score Model, we
compute a QT of the temporal evolution of AD-related bio-
markers by temporally aligning longitudinal data for indi-
viduals based on the similarity of a collection of
biomarkers for individuals who are NL or have MCI or
AD dementia. The QT reflects change in biomarkers as a
function of a latent disease stage indicator that is simulta-
neously estimated per individual in the model. Our model
enables the characterization of the trajectories in time
domain, thereby facilitating the interpretation and applica-
bility of our results to clinical settings. The estimated tempo-
ral QT shows that verbal memory decline is detectable early
on the trajectory to MCI and AD. The temporal evolution is
also marked by changes in hippocampal volume, cerebrospi-
nal fluid (CSF) amyloid (Ab1242), total tau (t-tau), and phos-
phorylated tau (p-tau181p), as well as brain glucose
metabolism and global measures of cognition and mental
status. We demonstrate that the estimated latent disease pro-
gression variable is associated with known risk factors for
late-onset AD and clinical diagnosis. Finally, we predict
AD dementia onset age using baseline data in a disjoint
testing set, achieving a root mean square error (RMSE) of
,1:5 years. Our results provide insights into the natural his-
tory of late-onset AD starting with the preclinical stages. The
estimated QT can be used to estimate individualized latent
disease stages given a collection of biomarker measurements
and predict future conversion to AD.
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2. Method
Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 as a public-private partnership, led by Prin-
cipal Investigator Michael W. Weiner, MD. The primary
goal of the ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neuropsy-
chological assessment can be combined to measure the pro-
gression of MCI and early AD. Specifically, we used the
ADNI data prepared for the Alzheimer’s Disease Modelling
Challenge and followed the recommendations prescribed in
this document for easing the comparison with other QTs for
the progression of AD.
2.1. Participants
We used data for 1706 participants with 6880 visits from
ADNI 1/GO/2. Clinical diagnoses of MCI and AD dementia
were determined by the ADNI Conversion Committee ac-
cording to the criteria described in the ADNI protocol. We
designated data for approximately 80% of the individuals
selected at random as the training set (1369 individuals
with 5533 visits). We designated the data for the remaining
individuals, excluding 67 individuals with AD at baseline, as
the testing set (270 individuals with 1165 visits) for evalu-
ating the performance of age at AD onset prediction. Partic-
ipant demographics are presented in Table 1. We compared
demographic variables by diagnostic category using theWil-
coxon rank-sum test for continuous variables and Fisher’s
exact test for categorical variables.
2.2. Biomarkers and cognitive measures
We computed a QT of the temporal evolution of the
following AD-related biomarkers: CSF Ab1242, p-tau181p,
t-tau; intracranial volume-adjusted hippocampal volume;
brain glucose metabolism measured by fluorodeoxyglucose
PET; verbal memory measured by Rey Auditory Verbal
Learning Test immediate recall (sum score across 5 learning
trials) [23]; mental status measured by the Mini–Mental
State Examination (MMSE) [24]; and AD and dementia in-
dicators as measured by the Alzheimer’s Disease Assess-
ment Scale-Cognitive 13-item scale [25] and the Clinical
Dementia Rating-Sum of Boxes [26]. These measures
were selected based on their demonstrated involvement in
the progression of AD and closely mirror those selected
for analysis with an earlier version of our model [6].
We selected visits with at least 5 of these 9 measures for
inclusion in our analysis.
2.3. Progression score model
We reformulated the previously described progression
score models [6,7] using a Bayesian framework where
biomarker trajectories are modeled using basis functions.
Compared with linear or sigmoid functions used in our
previous applications, basis functions allow for much
richer models of biomarker trajectories. We make the
following modeling assumptions:
1. Changes in biomarkers relative to one another in the
progression from a NL state to AD dementia can be
characterized uniquely.
2. Any deviation from this unique characterization of
biomarker changes along the disease spectrum is
assumed to be measurement noise.
3. Given enough time, all individuals will exhibit
biomarker levels seen in AD dementia; however, an
individual’s progression might be slow enough that
AD-level biomarkers will not be attained during the
individual’s life span.
2.4. Continuous-time model
We first describe the model in continuous time. We then
discretize it for fitting the parameters. The model describes
biomarker values collectively as a function of age using a
two-level composition. First, there is a subject-dependent
exponential mapping of age t to PS s:
vs
vt
5as; with sðt0Þ5g; (1)
where a.0 is a global parameter and g.0 is a subject-
specific variable. t0 is a fixed age, here t0 5 70, so that g is
the PS at 70 years. This model is partially motivated by Je-
dynak et al.[6, Fig. 4] and Bilgel et al. [7, Fig. 6 right]. In
both applications, the PS is an affine function of age for
each subject, yet Eq. 1 provides a reasonable approximation.
Solution of Eq. 1 is given by
s5f ðt;gÞ5geaðt2t0Þ (2)
Second, the vector of biomarker values at time t is
modeled with a monotonic function of the PS for each
biomarker added to a correlated noise:
yðtÞ5gðf ðt;gÞ;uÞ1εðtÞ (3)
Monotonicity of g is required for model identifiability.
2.5. Time from diagnosis
Diagnostic events include transitions from NL or MCI to
AD. The aforementioned model allows for the computation
of biomarker trajectories as a function of time from a diag-
nosis. Let ~s be the PS corresponding to a diagnosis. For
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The time from diagnosis for this subject at age t is
thus u5 t2 ~tð~sÞ. Biomarker trajectories as a function




We now describe the discrete-time model and the priors.














where tij is the age of subject i at visit j, and half2N is
the half-normal distribution. The choice of t0 is important
for the interpretation of g. At t5 t0, the PS of individual
i is equal to gi. Furthermore, the parameter sg reflects
the variability in the PSs at age t0. In this study, we
let t0570 so that it is reasonably close to the mean
age of our sample at baseline. We use half-normal hy-
perpriors on sa and sg, with their scale parameters fixed











Given K biomarkers, their trajectory models








where L is a diagonal matrix with Lkk 5 lk, C is a correla-
tion matrix, and LKJ is the random correlation matrix distri-
bution described by Lewandowski et al. [27]. We let n51 for
a uniform distribution over correlation matrices.
We consider logistic basis functions to characterize






























where uk 5 fpk; ak1;.; akZ ; bkg, with the constraint that
akz.0 ck; z to ensure monotonicity. pk is a categorical
random variable with equally likely observations {21,
11} to determine whether the trajectory is decreasing or
increasing, [˛RZ is a prespecified set of Z basis function lo-
cations, and s2basis determines the slant of each basis
function.
Assuming that all biomarker observations yijk have been
standardized to have zero mean and unit standard deviation




The standard deviation or scale parameter of each is fixed
at a large value (i.e., 10) such that the priors are essentially
uninformative. In the absence of data, these priors slightly
favor flat “trajectories” for the biomarkers.
Table 1
Participant demographics at baseline
Characteristic
Training set Testing set
NL, n5 405 MCI, n5 698 AD, n5 266 NL, n5 114 MCI, n5 156
Age 74.5 (5.81) 72.8 (7.62) 74.9 (7.71) 73.3 (5.78) 73.5 (7.40)
Male 197 (48.6%) 413 (59.2%) 149 (56.0%) 56 (49.1%) 91 (58.3%)
White 372 (91.9%) 651 (93.3%) 246 (92.5%) 100 (87.7%) 146 (93.6%)
Education 16.3 (2.62) 15.9 (2.85) 15.3 (3.02) 16.5 (2.97) 16.0 (2.85)
Single ε4 105 (26.0%) 280 (40.2%) 132 (50.0%) 32 (28.1%) 56 (35.9%)
ε4=ε4 7 (1.73%) 75 (10.8%) 46 (17.4%) 5 (4.39%) 18 (11.5%)
No. of visits 4.21 (2.28) 4.45 (1.97) 2.71 (1.14) 4.25 (2.27) 4.37 (2.04)
Follow-up 3.15 (2.38) 2.75 (1.84) 1.14 (0.84) 3.14 (2.44) 2.80 (1.99)
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; NL, cognitively normal.
NOTE. Continuous variables are reported as “mean (standard deviation)” and categorical variables are reported as “count (percentage)”.
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2.7. Model fitting
We conducted Markov chain Monte Carlo sampling to
generate posterior samples, using the No-U-Turn Sampler
step method [28] for continuous variables and a
Metropolis-within-Gibbs step method optimized for binary
variables for pk. Nonnegative variables were log-
transformed to allow for unconstrained optimization. For
visits with missing biomarker measurements, only the avail-
able measurements contributed to the model fitting proced-
ure. We used the PyMC3 Python package for model
specification and fitting [29]. Model fitting was performed
using training data.
We used Z55 logistic bases, with [z equally spaced be-
tween 0 and 10 and s2basis 5 1. We then fitted a series of
models:
1. sa, sg, and C were fixed at 0.05, 5.0, and the identity
matrix IK!K , respectively. For tuning the sampling pa-
rameters, we obtained 300 samples, which were then
discarded. The following 300 samples were used for
model parameter estimation.
2. Next, we removed the constraint fixing the correlation
matrix C. Samples obtained from the previous step
were used to initialize uk, lk, ai, bi, pk, and missing
biomarker observations yijk. We continued to fix
sa50:05 and sg 5 5:0. This model was fitted using
the longitudinal data set, with 200 tuning 1 200
samples.
3. Finally, we removed the constraints fixing sa and sg.
Samples obtained from the previous step were used to
initialize all previously estimated parameters, and we
fitted this model using 2000 tuning 1 2000 samples.
Fig. 1. Estimated population-level biomarker trajectories as a function of progression score s; s is plotted on a natural logarithm scale so that the x-axis is linear
in time. Mean trajectories are plotted in black, along with their 95% credible intervals. Longitudinal data points for 100 randomly sampled individuals per diag-
nostic category are shown. Biomarker z-scores, shown on the right-hand-side y-axes, were computed using mean and standard deviations at baseline across 1369
in the training set. Abbreviations: Ab, amyloid b; CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; PET, positron emission tomography; RAVLT, Rey Audi-
tory Verbal Learning Test; ADAS13, Alzheimer’s Disease Assessment Scale-Cognitive 13-item scale; MMSE,Mini–Mental State Examination; CDR-SB, Clin-
ical Dementia Rating-Sum of Boxes.
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2.8. Correlates of progression scores
To understand correlates of the individualized PS esti-
mated by our model, we performed a multiple linear regres-
sion analysis using the training data set investigating age,
education, sex, apolipoprotein E (APOE) ε4 status, and
clinical diagnosis as predictors of PS at baseline.
2.9. Biomarker trajectories as a function of time from AD
dementia
For each of the last M5200 Monte Carlo iterations, we
drew a sample ~s
ðmÞ
AD from the distribution of s at the first visit
with an AD diagnosis among individuals who converted
from NL or MCI to AD for the mth Monte Carlo iteration
(excluding individuals who reverted) and computed the
curve u1gðf ðu1~tð~sðmÞADÞ;gðmÞi Þ;uðmÞÞ for each individual i
in the training set. The resulting MN biomarker curves,
where N is the number of individuals in the training set,
were used to characterize the mean curve and its 95% inter-
val. To check if our estimated trajectories agreed with the
time from onset values available in the data set, we plotted
the computed curves, superimposed on a scattergram of
the biomarker data versus observed time from onset.
2.10. Prediction of time to diagnosis
Age at the first occurrence of an AD dementia diagnosis
for each individual who is NL or MCI at baseline was
considered as the age at dementia onset. Using the known
age at dementia onset data in the training set, we trained a
linear regression model with time to dementia onset from
baseline as the outcome and baseline PS as the independent
variable.
To make predictions for time to dementia onset in the
testing set, we first computed a PS for each individual at
baseline given the trained PS model. The trained linear
regression model was then applied to these baseline PSs to
make predictions for time to dementia onset for each
individual in the testing set.
We assessed the performance of our onset age estimation
by computing the RMSE between the predicted and
observed onset ages for individuals whose onset ages are
known (i.e., for whom diagnostic conversion was observed
in the longitudinal data set). This analysis is a biased reflec-
tion of the accuracy of onset age prediction given that it is
restricted to those who convert to AD. To obtain measures
based on all individuals regardless of their conversion status,
we estimated Kaplan-Meier survival curves based on our
predictions and observed onset ages. Survival curve estima-
tion incorporates data for all individuals by assuming that
AD conversion will occur after the last visit for individuals
who did not convert during the study. For computing the
Kaplan-Meier curves using observed data, event was defined
as the first visit with an AD diagnosis following a visit with
an NL or MCI diagnosis. We right-censored using age at last
visit if the individual remained NL or MCI. For computing
the Kaplan-Meier curves using predicted data, if onset was
“predicted” to occur before baseline visit, age at onset was
set to baseline age. We right-censored using age at last visit
if the predicted onset age was greater than the age at last
visit. We compared these two curves using the log-rank
test c2 statistic.
We repeated the linear regression models using age, each
biomarker, age 1 each biomarker, all biomarkers, and
age 1 all biomarkers as independent variable(s). We also
ran linear regression models using PS and its combinations
with age and/or g as independent variable(s). An intercept
was included in all linear regression models. We then used
permutation tests to compare the RMSE and c2 of the best
model without PS to those of the best model with PS. The
permutation test involved randomly swapping the onset
ages predicted by the models being compared and
computing the differences in RMSE and c2 between the
two models. This was repeated 2000 times to obtain a distri-
bution for RMSE difference and a distribution for c2 differ-
ence under the null hypothesis of equality between models.
The observed difference was then quantified against this null
distribution using a two-tailed test.
Fig. 2. Box and swarm plots of (A) baseline age, (B) estimated g, and (C) estimated progression score s at baseline by baseline diagnosis for individuals in the
training set. g and s are plotted on a natural logarithm scale. All pairwise comparisons were statistically significant (all P , 0.0013), with the exception of
baseline age comparison between NL and AD. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; NL, cognitively normal.
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Finally, we compared the prediction performance of PS
computed using our model to the performance of “disease
age” computed using two previously proposed models of
AD progression (see Appendix C for details).
2.11. Reproducible research
We provide the code used for these analyses and all the
software required to run it as a docker image accessible
via https://hub.docker.com/r/bilgelm/bayesian-ps-adni/.
3. Results
Participant demographics are presented in (Table 1). Dif-
ference in the proportions of NL and MCI diagnoses at base-
line between training and testing sets was not statistically
significant (Fisher’s exact test, P5 0.79). There were no sta-
tistically significant differences between training and testing
sets at baseline by diagnostic category in age, sex, race, ed-
ucation, APOE ε4 genotype, number of visits, or duration of
follow-up.
3.1. Fitted progression score model
Assessment of the traceplots (Fig. 1) and the Geweke
scores (Fig. 2) for the final model suggested convergence
of the sampler. Estimated biomarker trajectories as a func-
tion of PS are presented in Fig. 1. The resulting temporal
QT revealed early changes in verbal memory. The temporal
evolution was also marked by changes in hippocampal vol-
ume and CSF Ab1242, tau, and p-tau, as well as
fluorodeoxyglucose PET and remaining cognitive measures.
3.2. Correlates of progression scores
Box plots of the estimated subject-specific variable g and
baseline s revealed differences among NL, mild cognitively
impaired, and demented individuals. These group-wise dif-
ferences were greater than those observed with age
(Fig. 2). Older age, male sex, fewer years of education, the
number of APOE ε4 alleles, and MCI or AD diagnoses
were associated with higher PS at baseline (Table 2).
3.3. Time from diagnosis
Biomarker trajectories as a function of time from AD
diagnosis are shown in Fig. 3.
Among predictionmodels that did not include PS as an inde-
pendent variable, themodelwith the lowestc2 was the onewith
all 9 biomarkers (c2 5 20:5;RMSE5 1:58), whereas addition-
ally including age yielded the model with the lowest RMSE
(c2 5 21:1; RMSE5 1:57) (Table 3). Among models with
PS, including age in addition to PS yielded the model with
the lowest c2 (c2 5 1:68;RMSE5 1:49), whereas the model
withPSonly had the lowestRMSE(c2 5 2:00;RMSE5 1:48).
Results of age at AD onset prediction based on the linear
regression model with PS and age are shown in Fig. 4. The
Kaplan-Meier curve computed using predicted onset ages
tracked the observed curve closely (Fig. 4B). We used the
log-rank test to compare the curve based on predicted onset
ages to the curve based on observed onset ages. The differ-
ence between the curves based on predicted and observed
onset ages was not statistically significant based (log-rank
test P 5 0.2).
We compared the performance of the model with all 9
biomarkers to that of the model with PS1 age because these
models had the lowest c2 measures. Based on permutation
testing, the difference in RMSE (P 5 0.75) or c2 (P 5
0.08) of the two models was not statistically significant. Un-
like the predictions based on PS1 age, predictions based on
all 9 biomarkers yielded a survival curve that was different
from the survival curve based on the observed ages (log-rank
test, P , 0.0001).
Results of experiments investigating the predictive perfor-
mance of disease age computed using two previously pro-
posed models of AD progression are presented in the lower
portion of Table 3. The performance of the disease age
computed by Latent Time Joint Mixed effects Model [11]
is very similar to that of age. The disease age computed using
Gaussian Process Progression Model [15] results in a small
RMSE and maximum absolute error, both of which are mea-
sures computed using only the individuals who convert; how-
ever, the survival curve–based measures, which take into
account all individuals regardless of conversion, are poorer.
4. Discussion
We presented a model for aligning short-term longitudi-
nal data across individuals to characterize long-term trajec-
tories of a collection of biological and cognitive
measurements that are implicated in AD. We applied our
model to individuals who are NL or have MCI or AD
dementia to estimate a QT of AD progression using the
ADNI data set and recommendations presented in
the Alzheimer’s Disease Modelling Challenge. We
Table 2
Result of multiple linear regression analysis investigating the associations of
age, sex, education, APOE ε4 genotype, and clinical diagnosis with
estimated progression score s at baseline
Independent variable Estimate SE t-statistic P value
Intercept 23.72 0.545 26.83 ,0.001
Age 0.0869 0.006 14.1 ,0.001
Male sex 0.303 0.089 3.40 0.001
Education 20.0619 0.016 23.98 ,0.001
APOE ε4 heterozygous 0.719 0.094 7.63 ,0.001
APOE ε4 homozygous 1.34 0.158 8.50 ,0.001
MCI 2.45 0.103 23.9 ,0.001
AD dementia 5.13 0.132 38.8 ,0.001
Abbreviations: APOE, apolipoprotein E; AD, Alzheimer’s disease; MCI,
mild cognitive impairment; SE, standard error.
NOTE. Five individuals were excluded due to missing APOE informa-
tion. 1364 observations were used to fit the model, yielding an R2 5
0.635, an adjusted R2 5 0.633, F-statistic 5 336.7, and Prob(F-statistic)
,0.0001.
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demonstrated that progression along our estimated temporal
QT reflects AD processes by showing its association with
clinical diagnosis and known AD risk factors, as well as
by quantifying the accuracy of our model in predicting age
at onset of AD dementia. The ability of our model to
leverage short-term data to obtain long-term biomarker tra-
jectories is highly relevant to the current need in clinical trial
design for predicting whowill develop cognitive impairment
and AD dementia over time.
We found that the PS computed based on AD-related
neuropathology, neurodegeneration, and cognitive mea-
sures were associated with age, APOE ε4 positivity,
which is the most influential known genetic risk factor
for sporadic AD [30], and clinical diagnoses of MCI
and AD. We also observed higher PS among men and
a negative association between PS and years of educa-
tion. Associations with APOE ε4 and clinical diagnoses
provided evidence that our QT, which was constructed
without these pieces of information, is reflective of AD
progression. Although we recognize that there is hetero-
geneity in individual presentations across the biomarkers
considered in our model and that not every individual
included in our analyses is necessarily on an AD
pathway, the strong associations we observed between
PS and AD diagnosis as well as AD risk factors suggest
that the estimated trajectories are mainly indicative of
age- and disease-related changes that occur along the
progression toward AD dementia.
Fig. 3. Estimated biomarker trajectories as a function of time from initial AD dementia diagnosis are shown with the black curves, and the shaded areas depict
95% credible intervals. A value of 0 on the x-axis corresponds to the onset of AD dementia. Negative values are before the onset of AD dementia, and positive
values are after the onset of AD dementia. Biomarker z-scores, shown on the right-hand-side y-axes, were computed using mean and standard deviations at
baseline across 1369 individuals in the training set. Note that observed time from AD was not used in the estimation of the biomarker trajectories shown; tra-
jectories were obtained using the model fit. Scattergrams of observations are shown as a function of observed time from AD, color-coded by diagnosis, to allow
for a visual assessment of the agreement of the estimated trajectories with underlying data. Abbreviations: Ab, amyloid b; CSF, cerebrospinal fluid; FDG, fluo-
rodeoxyglucose; PET, positron emission tomography; RAVLT, ReyAuditory Verbal Learning Test; ADAS13, Alzheimer’s Disease Assessment Scale-Cognitive
13-item scale; MMSE, Mini–Mental State Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes.
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Our QT was consistent with our previous findings in
the ADNI [6]. By modifying our previously described
progression score models [6,7] to include a global parameter
governing the relationship between disease stage and rate of
progression, we were able to depict biomarker trajectories as
a function of time from AD diagnosis. This innovation
enabled a more easily interpretable characterization of the
natural history of AD starting in preclinical stages.
Ourmethod achieved,1:5-yearRMSE in predicting age at
onset ofADover the course of 0.48 to 9.0 years. It is difficult to
compare the performance of our prediction with results re-
ported in the literature based on previousmethods given differ-
ences in samples and model features used. Oxtoby et al. [5]
reported an RMSE of 1.3 years for predicting age at onset
over the course of 3.0 years in the context of dominantly in-
herited AD based on CSF, MRI, and PET biomarkers. Vogel
et al. [22] reported an R2 value of 0.15 using the ADNI data
set for predicting years to conversion to MCI or AD based on
functional and structural MRI measures. We fitted two previ-
ously proposed models and compared the performance of dis-
ease agecomputedby thesemodels in predictingageat onset of
AD in the same data set to the performance of PS computed
from our model. PS computed using our model achieved the
best predictive performance under every measure. It is neces-
sary to continue model development in this area to enable
more accurate onset age predictions over longer time intervals.
A limitation of our model is the simplifying assumption of a
single pathway of biomarker changes from a NL state to AD
dementia. It is known that there is heterogeneity in longitudinal
progression in AD. Studying individuals who deviate from the
estimated QTmay be informative in understanding this hetero-
geneity, and models that relax the assumption of a single
Table 3
Prediction results based on linear regression models, presented for a select







RMSE Max. abs. err. c2 Max. vert. dist.
Age 1.80 6.78 46.6 0.491
RAVLT imm. 1.64 5.52 35.7 0.438
RAVLT imm. 1 age 1.64 5.46 34.5 0.437
All biomarkers 1.58 4.67 20.5 0.428
All biomarkers 1 age 1.57 4.63 21.1 0.437
PS 1.48 3.79 2.00 0.453
PS 1 g 1.48 3.75 1.72 0.453
PS 1 age 1.49 3.70 1.68 0.453
Comparison to disease age estimated from other methods
LTJMM [11],
ti;j50 1 di




2.20 5.80 18.3 0.466
This article, PS
(subset)
2.14 4.21 0.685 0.200
Abbreviations: RMSE, root mean square error; Max. abs. err., maximum
absolute error; c2, log-rank test statistic; Max. vert. dist., maximum vertical
distance between the survival curves based on predicted onset and observed
onset; RAVLT imm., Rey Auditory Verbal Learning Test immediate recall
(sum across learning trials); PS, progression score.
NOTE. The lower portion of the table presents the predictive performance
achieved using disease ages estimated using two existing models of AD pro-
gression, Latent Time Joint Mixed effects Model (LTJMM) and Gaussian
Process Progression Model (GPPM). Because the GPPM model had to be
fitted on a subset of the data, for comparison purposes, we also present
the predictive performance of PS computed using our model in this same
subset.
Fig. 4. (A) AD dementia onset ages predicted using the linear regression model with PS1 age vs. observed AD dementia onset age (for individuals with known
onset ages in the testing set). Time between baseline age and AD onset age (indicated by the size of the markers) varied between 0.48 and 9.0 years (median 1.6,
IQR 1.0-3.0). There were 18, 15, 10, and 3 participants whose true time to diagnosis was in the interval ð0:4;1:5Þ, ð1:5;2:5Þ, ð2:5;5:0Þ, and ð5; 9:1Þ, respectively.
The RMSEs corresponding to these ranges were 1.64, 1.06, and 0.84, 3.14. (B) Kaplan-Meier curves based on observed (red) and predicted (blue) AD dementia
onset ages.
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progression pathway will be necessary for a detailed analysis.
Weobserved the greatest variability around trajectory estimates
for CSFAb1242. This suggests that the timing of CSFAb1242
can vary at the individual level in relation to changes in other
biomarkers included in this study. Another limitation of our
study is that higher PS indicates both age- and AD-related
changes in the examined biomarkers. Understanding changes
that occur with AD as distinct from age-related changes is clin-
ically important. However, this is a challenging goal given that
there is no scientific consensus regarding the definition of
healthy aging. Several studies have approached this problem
by including age and other demographic variables as covariates
in addition to a disease stage variable [11,31,32] or by
regressing out their effects before model fitting [5,33,34],
whereas others have not included covariates to characterize
trajectories that explain the natural history of AD dementia,
including biological and cognitive changes that occur due to
aging in addition to AD [4,6–9,13,15]. We formulated our
goal with this study as the characterization of the natural
history of AD dementia, including biological and cognitive
changes that occur due to aging in addition to AD pathology,
and therefore did not include an adjustment for age or any
other demographic variables.
In conclusion, our method allows for the estimation of indi-
vidualized latent disease progression indicators and
population-level biomarker trajectories from longitudinal
data. The estimated temporal QTofAD provides a mechanism
for localizing individuals along biomarker trajectories based
on multivariate data. Individualized PSs can be used as longi-
tudinal composites to investigate associations with risk factors
and outcomes. Furthermore, the ability to obtain individual-
ized estimates of age at AD onset can allow for better partic-
ipant recruitment in clinical trials aimed at preclinical AD.
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RESEARCH IN CONTEXT
1. Systematic review: The authors performed searches
using PubMed and Google Scholar to cover relevant
literature featuring the following keywords: Alz-
heimer, dementia, progression, staging, statistical
model, Bayesian model, predict, onset age, and age
at onset. Relevant scientific literature citing and cited
by papers found through these searches were also
included in the systematic review.
2. Interpretation: Our model provided a quantitative
template of Alzheimer’s disease (AD) progression,
demonstrating early changes verbal memory, hippo-
campal volume loss, and cerebrospinal fluid mea-
sures of amyloid and tau. Our method enabled
prediction of AD dementia onset age with a root
mean square error of,1.5 years, and predicted onset
ages yielded a survival curve that closely matched
the survival curve based on observed onset ages.
3. Future directions: Future work should investigate
how the proposed progression scoremodel can be op-
erationalized to enable decisions regarding partici-
pant recruitment, monitoring, and treatment in
research studies and clinical trials.
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